
Repligen Corporation (RGEN)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn more- Previous Close
188.64 - Open
175.37 - Bid 163.78 x 200
- Ask 186.99 x 200
- Day's Range
171.23 - 180.30 - 52 Week Range
100.99 - 198.87 - Volume
4,472,060 - Avg. Volume
1,126,704 - Market Cap (intraday)
11.234B - Beta (5Y Monthly) 1.08
- PE Ratio (TTM)
-- - EPS (TTM)
-0.21 - Earnings Date Oct 27, 2026
- Forward Dividend & Yield -- (0.00%)
- 1y Target Est
202.22 - Morningstar Rating Rating available with Stock Picks access
Recent News
View MorePerformance Overview
Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Earnings Trends
View MoreAnalyst Insights
View MoreStatistics
View MoreValuation Measures
-
Market Cap
11.98B
-
Enterprise Value
11.81B
-
Trailing P/E
246.81
-
Forward P/E
68.85
-
PEG Ratio (current)
--
-
Price/Sales (ttm)
13.23
-
Price/Book (mrq)
5.11
-
Enterprise Value/Revenue
14.65
-
Enterprise Value/EBITDA
92.66
Financial Highlights
Profitability and Income Statement
-
Profit Margin
-1.47%
-
Return on Assets (ttm)
1.40%
-
Return on Equity (ttm)
-0.57%
-
Revenue (ttm)
805.61M
-
Net Income Avi to Common (ttm)
-11.8M
-
Diluted EPS (ttm)
-0.21
Balance Sheet and Cash Flow
-
Total Cash (mrq)
862.98M
-
Total Debt/Equity (mrq)
33.09%
-
Levered Free Cash Flow (ttm)
111.58M
Compare
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Company Insights
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports
View More-
Repligen Earnings: Strong Growth and Margin Expansion Despite Filtration and Inflation Headwinds
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, and other life science companies. It sells four main product categories: filtration and fluid management is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia-Pacific contribute about 44%, 37%, and 19% of revenue, respectively.
-
Lowering target price to $185.00
REPLIGEN CORP has an Investment Rating of HOLD; a target price of $185.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
-
Raising target price to $188.00
REPLIGEN CORP has an Investment Rating of HOLD; a target price of $188.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
-
What does Argus have to say about RGEN?
REPLIGEN CORP has an Investment Rating of HOLD; a target price of $184.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.






